Hangzhou Weibenyuan Pharmaceutical

Hangzhou Weibenyuan Pharmaceutical is a clinical-stage biotechnology company based in China that specializes in the discovery and development of innovative small molecule drugs, with a core focus on Targeted Protein Degradation (TPD) technologies. The company's lead program, WBY-001, is a potent Bruton tyrosine kinase (BTK) degrader designed to overcome resistance issues associated with traditional BTK inhibitors in B-cell malignancies. Weibenyuan leverages its proprietary PROTAC platform to design highly selective degraders for high-value targets in oncology and immunology. The company aims to provide next-generation therapeutic solutions for patients with refractory or relapsed cancers.